Stock listing
850501 Stock Price, News, Filings & Events — Bristol-myers Squibb Company
Selected listing: 850501 · LSX · EUR · DE
This page tracks Bristol-myers Squibb Company's 850501:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 850501:LSX. 850501:LSX is the stock-level entry point for investors researching Bristol-myers Squibb Company, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- 850501:LSX
- Asset type
- Stock
- Market cap
- $136.00B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LSX
- Currency
- EUR
Bristol-myers Squibb Company 850501:LSX stock context
This page tracks Bristol-myers Squibb Company's 850501:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 850501:LSX. 850501:LSX is the stock-level entry point for investors researching Bristol-myers Squibb Company, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Bristol-myers Squibb Company
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
September 30, 2026
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
September 25, 2026
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
September 25, 2026
New Member Alert: RAAP WELCOMES BRISTOL MYERS SQUIBB! BMS Joins as Newest Member of RAAP
September 23, 2026
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
September 23, 2026
Bristol-myers Squibb Company earnings calls
Bristol-Myers Squibb Company (BMY) Q2 2026 Earnings Call
July 30, 2026 · Replay with transcript and chapters
Bristol-Myers Squibb Company (BMY) Q1 2026 Earnings Call
April 30, 2026 · Replay with transcript and chapters
Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call
February 5, 2026 · Replay with transcript and chapters
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call
October 30, 2025 · Replay with transcript and chapters
Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call
July 31, 2025 · Replay with transcript and chapters
Bristol-Myers Squibb Company (BMY) Q1 2025 Earnings Call
April 24, 2025 · Replay with transcript and chapters
Research Bristol-myers Squibb Company
Bristol-myers Squibb Company investor report
Review AI stock analysis and investor report context for 850501:LSX.
Bristol-myers Squibb Company company profile
View the public company page for Bristol-myers Squibb Company on 6ix.
Bristol-myers Squibb Company news
Read company news and market updates connected to Bristol-myers Squibb Company.
Bristol-myers Squibb Company investor events
Find investor webinars, events, and replay context for Bristol-myers Squibb Company.
Alternate listings
BMY:NYSE
US · USD
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
BMY:BCBA
AR · ARS
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
BRM:GETTEX
DE · EUR
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
BRM:TRADEGATE
DE · EUR
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
BRM:XETR
DE · EUR
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
BMY:BMV
MX · MXN
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
850501:LS
DE · EUR
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
BRM:SWB
DE · EUR
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
BMY:BOATS
US · USD
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
BMYB34:BMFBOVESPA
BR · BRL
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
1BMY:MIL
IT · EUR
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.
BRM:FWB
DE · EUR
Alternate listing for Bristol-myers Squibb Company; the primary context on this page is 850501:LSX.